Dutch interest group calls for excessive drug-pricing probe
An advocacy group has said it will ask the Netherlands’ competition authority to investigate a drugmaker for setting excessive prices for the only drug that is available on the market for treating a rare genetic disease.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.